By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Genomic Health, Inc. 

301 Penobscot Drive

Redwood City  California  94063  U.S.A.
Phone: 650-556-9300 Fax: 650-556-1132


Genomic Health, Inc. (NASDAQ: GHDX) is the world’s leading provider of genomic-based diagnostic tests that address the overtreatment of early stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results throughout the cancer patient’s journey, from screening and surveillance, to diagnosis, to treatment selection and monitoring. Genomic Health’s lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease, and the Oncotype DX prostate cancer test, which predicts disease aggressiveness in men with low risk disease. As of June 30, 2013, more than 19,000 physicians in over 70 countries had ordered more than 375,000 Oncotype DX tests. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.

For more information, please visit,
and follow the company on Twitter: @GenomicHealth. To learn more about Oncotype DX tests, visit:
, and

Key Statistics

Ownership: Public

Web Site: Genomic Health, Inc.
Symbol: GHDX

Medical Device

Company News
Veteran Genomic Health, Inc. (GHDX) Executive, Dean Schorno, CPA, Joins Adaptive Biotechnologies As Chief Financial Officer 6/20/2014 7:06:10 AM
Genomic Health, Inc. (GHDX) Announces Positive Topline Results Of Second Large, Independent Validation Study Of Oncotype DX® In DCIS Breast Cancer 6/11/2014 6:36:15 AM
Genomic Health, Inc. (GHDX) Demonstrates The Importance Of Utilizing Multiple Biological Pathways To Predict Tumor Behavior In Prostate And Renal Cancers 6/3/2014 9:31:04 AM
Genomic Health, Inc. (GHDX) Release: Multiple Studies Presented At American Society of Clinical Oncology Annual Meeting Demonstrate Unique, Practice-Changing Impact Of Oncotype DX® To Optimize Cancer Care 6/2/2014 6:51:22 AM
Genomic Health, Inc. (GHDX) Release: Oncotype DX® Breast Cancer Test Predicts Late Recurrence Five To 15 Years Out 5/29/2014 8:49:46 AM
Genomic Health, Inc. (GHDX) To Present At Two Upcoming Investor Conferences 5/23/2014 6:32:47 AM
Genomic Health, Inc. (GHDX) Announces Data Reinforcing Robustness Of Oncotype DX® Prostate Cancer Test At 2014 American Urological Association (AUA) Annual Meeting 5/21/2014 8:21:31 AM
European Urology Published Groundbreaking Results From Three Studies Demonstrating Genomic Health, Inc. (GHDX)'s Oncotype DX® Test Predicts Prostate Cancer Aggressiveness At Diagnosis 5/19/2014 9:06:50 AM
Genomic Health, Inc. (GHDX) Announces First Quarter 2014 Financial Results And Business Progress 5/7/2014 6:36:59 AM
Genomic Health, Inc. (GHDX) Release: Oncotype DX® Changes Treatment Decisions In 45 Percent Of Stage II Colon Cancer Patients 5/2/2014 9:03:51 AM